Elie Saab, MD
Pulmonary Disease · Portsmouth, OHNPI 1447218169
Payments from drug & device makers
Across 36 payments — averaging $459.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$8K
- Intuitive Surgical$6K
- Pulmonx Corporation$2K
- Olympus Corporation Of The Americas$223
- Sanofi$178
- Sanofi-aventis U.S. LLC$99
- plus $77 from 1 others
What the payments were for
- Travel & lodging$2,34514%
- Food & beverage$7725%
- Education$5,67634%
- Other$7,74647%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philips North America LLC | 1 | $7,746 |
| Intuitive Surgical | 8 | $5,791 |
| Pulmonx Corporation | 13 | $2,425 |
| Olympus Corporation Of The Americas | 5 | $223 |
| Sanofi | 7 | $178 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Actelion Pharmaceuticals US, Inc. | 1 | $77 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Trilogy 100$7,746
- Da Vinci Surgical System$5,655
- Pulmonx Endobronchial Valve EBV$1,146
- ZEPHYR ENDOBRONCHIAL VALVE$1,018
- PULMONX CHARTIS TABLET CONSOLE$1,018
- CHARTIS CATHETER$1,018
- ZEPHYR DELIVERY CATHETER$1,018
- Olympus Bronchoscopes$127
- Olympus Capital Accessories$127
- Olympus Respiratory Accessories$127
- DUPIXENT$110
How this compares
$16,538 in reported general payments places this provider in the 80th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 40 | $559,330 |
| Dupixent PenDupilumab | 56 | $198,646 |
| NucalaMepolizumab | 19 | $99,042 |
| TezspireTezepelumab-Ekko | 12 | $54,434 |
| Pirfenidone | 12 | $51,811 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 73 | $51,797 |
| Spiriva RespimatTiotropium Bromide | 59 | $31,598 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 37 | $18,090 |
| EliquisApixaban | 18 | $16,604 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $14,616 |
| FarxigaDapagliflozin Propanediol | 20 | $14,119 |
| Ambrisentan | 11 | $13,682 |
| Spiriva HandihalerTiotropium Bromide | 14 | $8,295 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $6,312 |
| Striverdi RespimatOlodaterol Hcl | 22 | $5,543 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Portsmouth
- Bruce CorserCincinnati$8.2M
- Edward CordascoColumbus$8M
- Kristin HighlandCleveland$3.2M
- Brian ZenoColumbus$2.9M
- Jean ElwingCincinnati$2.4M
- Roy St JohnColumbus$1.9M
- Nishant GuptaCincinnati$1.5M
- Robert BaughmanCincinnati$1.1M
- Francis McCormackCincinnati$1.1M
- Leslie TolleCleveland$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.